In recent weeks there has been enormous profile about growing resistance to antibiotics, and the resultant rise in deaths from infections and superbugs. David Cameron appointed Jim O'Neill to head a Commission on this threat, and his findings supported urgent and sizeable investment into antibiotic research.
Motif Bio listed on AIM in April to further its development of novel antibiotics, and subsequently received a 'green light' from the FDA. The CEO, Graham Lumsden, and Chairman, Richard Morgan, will present their plans to investors via a webinar on 10th June.
The presentation will last approximately 30 mins and there will then be an opportunity for Q&A. If you would like to join them please register now:
After registering, you will receive a confirmation email containing information about joining the webinar.
If you would like to submit any questions for management ahead of the meeting please send them toben.ferguson@equitydevelopment.co.uk and our recent initiation note is attached.
